Inventiva (NASDAQ:IVA) Coverage Initiated by Analysts at Truist Financial

Research analysts at Truist Financial initiated coverage on shares of Inventiva (NASDAQ:IVA) in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage set a “buy” rating and a $13.00 price target on the stock. Truist Financial’s price target indicates a potential upside of 118.12% from the company’s current price.

A number of other brokerages also recently issued reports on IVA. Leerink Partners initiated coverage on Inventiva in a report on Monday, January 12th. They set an “outperform” rating and a $12.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a report on Thursday, January 22nd. UBS Group started coverage on Inventiva in a research report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price objective on the stock. Barclays initiated coverage on Inventiva in a report on Tuesday, January 27th. They set an “overweight” rating and a $18.00 target price for the company. Finally, HC Wainwright set a $24.00 price target on Inventiva and gave the stock a “buy” rating in a research note on Wednesday, January 28th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $16.56.

Inventiva Stock Performance

IVA stock opened at $5.96 on Thursday. The firm’s 50-day moving average price is $6.26 and its two-hundred day moving average price is $5.36. Inventiva has a 12-month low of $2.70 and a 12-month high of $7.98.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Creative Planning purchased a new stake in Inventiva in the second quarter worth about $32,000. Virtu Financial LLC purchased a new position in shares of Inventiva during the fourth quarter valued at approximately $60,000. XTX Topco Ltd bought a new stake in shares of Inventiva in the 4th quarter worth approximately $84,000. Cerity Partners LLC bought a new stake in shares of Inventiva in the 4th quarter worth approximately $93,000. Finally, NewEdge Advisors LLC purchased a new stake in shares of Inventiva in the 3rd quarter worth approximately $116,000. 19.06% of the stock is owned by hedge funds and other institutional investors.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.